ALNY FY 2011 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2011 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M-17.3% YoY

Gross Profit

$83M100.0% margin

Operating Income

-$55M-66.2% margin

Net Income

-$58M-69.7% margin

EPS (Diluted)

$-1.36

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$88M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$282M

Total Liabilities

$164M

Stockholders' Equity

$118M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$100M	-17.3%
Gross Profit	$83M	$100M	-17.3%
Operating Income	-$55M	-$44M	-24.4%
Net Income	-$58M	-$44M	-32.5%